Protocol Ledger

NCT03957590 · Phase III · COMPLETED

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Interventional Phase III clinical trial protocol NCT03957590 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-06-11 Enrollment: 370 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03957590
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)370 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03957590
Protocol FieldVerified Registry Value
NCT IdentifierNCT03957590
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment370 participants (ACTUAL)
Registered Start Date2019-06-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03957590
Hospital Research SiteLocationSite Profile
Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chongqing Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI